SLXN biotech catalysts & pipeline

SILEXION THERAPEUTICS CORP · Data as of 2026-09-08

Upcoming catalysts

H2, 2026

Toxicology package for marketing approval planned for H2, 2026 Favorable Tolerability with No Systemic Toxicity or Organ Damage

early 2027

pre - IND meeting with FDA expected early 2027

Q1, 2027

IND application Q 1 , 2027

2028

2028 Trial Interim results Sample size adjustment